Bacteriophage therapy research
Phage therapy is an alternative way to treat bacterial infections. Phages are a bacterial virus that preys on bacteria - it targets a particular bacterium, then injects it with DNA to take it over and make more phages. The bacteria explode and die, expelling up to 300 new phages, which then search for their next target. Phage therapy could be an adjunct to standard antibiotic therapy and a way to combat antibacterial resistance.
New research centres dedicated to harnessing and evolving phage therapies have recently been established in the United States, Australia, Belgium, Israel and France — joining longstanding phage research centres in Poland and the Republic of Georgia. Yet, despite rising global interest in phages, Canada lags behind its international peers and it is not available as a treatment here.
A recent $5 million gift from an anonymous donor to U of T’s Temerty Faculty of Medicine is funding bacteriophage therapy research through:
- A Professorship in Bacteriophage Therapy Research and Innovation – awarded to Dr. Greg German.
- Expanding Canadian bacteriophage biobanking resources
- Establishing a bacteriophage therapy research accelerator fund.
Phage therapy news
A recent $5-million donation to the University of Toronto's Temerty Faculty of Medicine aims to establish the country as a leading center for phage therapy and accelerate research efforts.
Dr. Greg German and Dr. Jonathan Cook have conducted a comprehensive systematic review revealing over a century of safe and effective use of Phage Therapy. The team identified more than 1,400 unique human cases of Phage therapy for urinary tract infections since 1926, prompting efforts to raise awareness and consider it as a treatment option in Canada.